VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

被引：0
|
作者：
Patel, Manish R.
Juric, Dejan
Henick, Brian S.
Moore, Kathleen N.
Do, Doreen
Chapman, Joshua
Zhang, Hui
Roche, Maria
Newberry, Kate J.
Rinne, Mikael
Yap, Timothy A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-23-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-23-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
    Yap, Timothy A.
    Giordano, Antonio
    Hamilton, Erika P.
    LoRusso, Patricia
    Bowers, Michelle
    Basu, Cynthia
    Billotte, Stephane
    Delioukina, Maria
    Liu, Feng
    Yang, Jing
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors
    Kalinsky, Kevin
    Tolcher, Anthony W.
    Wang, Shushen
    Meric-Bernstam, Funda
    Winkler, Robert
    Li, Mingyu
    Sun, Xuemei
    Pan, Wentao
    Paudyal, Bishnuhari
    Liang, Zhiyan
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas
    Infante, Jeffrey R.
    Shapiro, Geoffrey I.
    Witteveen, Petronella O.
    Gerecitano, John F.
    Ribrag, Vincent
    Chugh, Rashmi
    Chakraborty, Abhijit
    Matano, Alessandro
    Zhao, Xumei
    Parasuraman, Sudha
    Cassier, Philippe A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [34] First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors
    Ge, X.
    Li, Q.
    Yuping, S.
    Wang, L.
    Li, Y.
    Wen, J.
    Xiao, F.
    Yao, L.
    Lin, J.
    Xie, Z.
    Sun, F.
    Zheng, A.
    Guo, Y.
    Li, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S164 - S165
  • [35] A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
    Yamamoto, Noboru
    Shimizu, Toshio
    Yonemori, Kan
    Kitano, Shigehisa
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Sudo, Kazuki
    Sato, Jun
    Tamura, Kenji
    Tomomatsu, Junichi
    Ono, Makiko
    Fukuda, Naoki
    Takahashi, Shunji
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1036 - 1046
  • [36] A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
    Noboru Yamamoto
    Toshio Shimizu
    Kan Yonemori
    Shigehisa Kitano
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Kazuki Sudo
    Jun Sato
    Kenji Tamura
    Junichi Tomomatsu
    Makiko Ono
    Naoki Fukuda
    Shunji Takahashi
    Investigational New Drugs, 2021, 39 : 1036 - 1046
  • [37] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
    Bahleda, R.
    Meric-Bernstam, F.
    Goyal, L.
    Tran, B.
    He, Y.
    Yamamiya, I
    Benhadji, K. A.
    Matos, I
    Arkenau, H-T
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
  • [38] SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6i
    Patnaik, Amita
    Novoa, Silvia Antolin
    Bellet-Ezquerra, Meritxell
    Bidard, Francois-Clement
    Boni, Valentina
    Brunet, Maxime
    Campone, Mario
    Garay, Carlos
    Gomez-Bravo, Raquel
    Howell, Sacha
    Jeselsohn, Rinath
    Lord, Simon
    Mazzei, Paolo
    De Miguel, Maria
    Roesch, Erin
    Stradella, Agostina
    Vanacker, Helene
    Vicier, Cecile
    Wander, Seth
    Clack, Glen
    McIntosh, Stuart
    CANCER RESEARCH, 2024, 84 (09)
  • [39] A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
    Dowlati, Afshin
    Vlahovic, Gordana
    Natale, Ronald B.
    Rasmussen, Erik
    Singh, Indrajeet
    Hwang, Yuying C.
    Rossi, John
    Bass, Michael B.
    Friberg, Gregory
    Pickett, Cheryl A.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4574 - 4584
  • [40] SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6i
    Clack, Glen
    Aksoy, Sercan
    Bellet-Ezquerra, Meritxell
    Bermejo, Begona
    Arslan, Cagatay
    Castro-Henriques, Maria
    Cicin, Irfan
    Gumus, Mahmut
    Hinojo-Gonzalez, Carmen
    Karadurmus, Nuri
    Cervantes, Denisse Lee
    Mejorada, Rebeca Lozano
    Jimenez, Emmanuel de la Mora
    Anton, Fernando Moreno
    Pernas, Sonia
    Pluard, Timothy
    del Valle, Carlos Zuloaga Fernandez
    Yazici, Ozan
    McIntosh, Stuart
    CANCER RESEARCH, 2024, 84 (09)
12345